Comparing two types of kidney treatments for patients with sepsis-related kidney injury
Efficacy of Convection-based Hemodiafiltration Compare With Diffusion-based Hemodialysis in Sepsis-associated Acute Kidney Injury: A Randomized Controlled Trial
This study is testing whether a new kidney treatment using convection-based hemodiafiltration works better than traditional hemodialysis for patients with kidney injury caused by sepsis.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 28 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Ramathibodi Hospital Academic / other |
| Locations | 1 site (Bangkok) |
| Trial ID | NCT06227104 on ClinicalTrials.gov |
What this trial studies
This clinical trial aims to evaluate the efficacy of convection-based hemodiafiltration (OL-HDF) compared to diffusion-based hemodialysis (SLED) in patients suffering from sepsis-associated acute kidney injury (S-AKI) who require kidney replacement therapy. The study will involve a stratified randomized controlled design, where patients will be allocated to either treatment group based on their hemodynamic stability. Key outcomes will include the percentage reduction in C-reactive protein (CRP), 30-day mortality rates, renal recovery, and length of hospital stay. The trial will take place at Ramathibodi Hospital and Chakri Naruebodindra Medical Institute in Thailand.
Who should consider this trial
Good fit: Ideal candidates for this study are adults over 18 years old with sepsis-associated acute kidney injury requiring kidney replacement therapy.
Not a fit: Patients who are pregnant, have end-stage kidney disease, or are receiving high doses of vasopressors may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved treatment options and outcomes for patients with sepsis-associated acute kidney injury.
How similar studies have performed: While there have been studies on hemodialysis methods, this specific comparison of convection-based versus diffusion-based treatments in sepsis-associated AKI is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Sepsis-associated AKI requiring KRT * Age \>18 years old Exclusion Criteria: * Pregnancy * Patients with end stage kidney disease who are currently receiving kidney replacement therapy (chronic hemodialysis, peritoneal dialysis, kidney transplantation) * Patient who has refused to consent * Patient who dead or aim to dead within 24 hours after randomization * Patient who is receiving very high dose of vasopressor (norepinephrine \> 1 mcg/kg/min) * Patient who is receiving CRRT at first randomization
Where this trial is running
Bangkok
- Ramathibodi Hospital — Bangkok, Thailand (Recruiting)
Study contacts
- Principal investigator: Chamanant Satjanon, MD — Ramathibodi Hospital
- Study coordinator: Chamanant Satjanon, MD
- Email: may.ninthnov@gmail.com
- Phone: +66896968108
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.